Skip to main content
Premium Trial:

Request an Annual Quote

Waters Plans New MS Headquarters in UK

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Waters today announced a land-purchase agreement with the Royal Bank of Scotland where it will build a new mass spectrometry headquarter in Wilmslow, Cheshire in the UK.

The new facility, to be situated on the 37-acre Stamford Lodge site, will bring together Waters' mass spec operations located on four separate sites in South Manchester and Altrincham. The facility will include state-of-the-art customer demonstration laboratories, R&D capabilities, and expanded manufacturing capacity.

The new headquarters "will be designed to accelerate the fate of innovation with increased access for the world's scientific thought leaders," said Brian Smith, Waters' vice president of MS business operations, said in a statement.

Final sale of the land is subject to planning and building permission from the Cheshire East Council. It is expected to open in 2013.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.